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Abstract
This study aimed to assess the efficacy and safety of combination treatment with lenalidomide and cetuximab in KRAS-
mutant metastatic colorectal cancer patients. This was a phase II multicenter, open-label trial comprising a safety lead-in
phase (phase IIa) to determine the maximum tolerated dose, and a randomized proof of concept phase (phase IIb) to
determine the response rate of lenalidomide plus cetuximab combination therapy. Phase IIa treatment comprised oral
lenalidomide (starting dose 25 mg/day) and intravenous cetuximab (400 mg/m2 followed by weekly 250 mg/m2) in 28-day
cycles. In phase IIb patients were randomized to either the phase IIa treatment schedule of lenalidomide plus cetuximab
combination therapy or lenalidomide 25 mg/day monotherapy. Eight patients were enrolled into phase IIa. One patient
developed a dose-limiting toxicity and the maximum tolerated dose of lenalidomide was determined at 25 mg/day. Forty-
three patients were enrolled into phase IIb proof of concept. Best response was stable disease in 9 patients and study
enrollment was terminated prematurely due to lack of efficacy in both treatment arms and failure to achieve the planned
response objective. The majority of adverse events were grade 1 and 2. In both phases, the adverse events most commonly
attributed to any study drugs were fatigue, rash and other skin disorders, diarrhea, nausea, and stomatitis. Thirty-nine
deaths occurred; none was related to study drug. The combination of lenalidomide and cetuximab appeared to be well
tolerated but did not have clinically meaningful activity in KRAS-mutant metastatic colorectal cancer patients.
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Introduction
It has been documented that colorectal cancer (CRC) is the
third most common cancer in men and second in women
worldwide, and around 10% of all malignancies are colorectal
tumors [1]. Approximately 40–50% of these colorectal tumors
have activating mutations in the KRAS (v-Ki-ras2 Kirsten rat
sarcoma viral oncogene homolog) gene [2].
KRAS is involved in cell signaling pathways, including the signal
transduction of the epidermal growth factor receptor (EGFR).
Anti-EGFR monoclonal antibodies (mAbs), panitumumab (Vecti-
bixH, Amgen Inc.) and cetuximab (ErbituxH, Merck KGaA), have
demonstrated efficacy in wild-type KRAS metastatic CRC (mCRC)
[3–6]. However, due to primary resistance these compounds have
little or no efficacy in mCRC cells harboring KRAS mutations
[7,8]. For patients with KRAS-mutated mCRC that is resistant to
or has relapsed after fluoropyrimidine-, oxaliplatin-, and irinote-
can-containing therapies, treatment beyond best supportive care is
very limited [9]. Several investigational agents, such as regorafenib
[10] and perifosine [11], are currently under evaluation in mCRC.
In a phase III study in mCRC patients, regorafenib showed
significantly better overall survival (OS) and progression-free
survival (PFS) than placebo; this benefit has been shown in the
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KRAS-mutated population as well [10]. In contrast, in a
randomized phase II study perifosine in combination with
capecitabine was suggested to be active in the refractory setting
[11], although a recently presented phase III study has not been
able to confirm these results [12].
Cetuximab is an anti-EGFR mAb that is indicated for treatment
of KRAS wild-type mCRC [13]. In addition to immune system
activation [14] and blockage of the EGFR signaling pathway
[15,16], many therapeutic mAbs also act through the mechanism
of interaction of the Fcc receptor (FccR) with immune complexes
triggering biological responses that include phagocytosis, release of
inflammatory mediators, antibody dependent cellular cytotoxicity
(ADCC), blockade of growth factor binding, enhancement of
antigen presentation, and platelet activation [17]. Genetic
variation in FccRs is suggested to play an important role in
disorders of the host defense system [18], immunohematologic
disease [19], and systemic autoimmune disease [20,21], as well as
in the efficacy of mAbs [22,23], at least for those that have an
immunoglobulin (Ig)G1 structure.
Lenalidomide (RevlimidH, Celgene Corporation) is an immu-
nomodulatory agent with antiangiogenic and antineoplastic
properties that has demonstrated efficacy and an acceptable
toxicity profile in multiple myeloma and myelodysplastic syn-
dromes [24–26]. Lenalidomide has also demonstrated antiangio-
genic activity in a CRC model [27]. In mice, daily administration
of lenalidomide reduced the rate of tumor growth significantly and
during histological analysis of the tumors, vast areas of necrotic
tissue were found [27].
In further preclinical studies, the combination of lenalidomide
plus cetuximab caused lysis of CRC cells, including cells with
KRAS mutations [28]. Lenalidomide enhanced natural killer (NK)
cell-mediated lysis of CRC cells coated with cetuximab by ADCC
[28]. Lysis of CRC cells was independent of KRAS mutational
status since ADCC bypasses this defect in the proliferative
pathways in the cell [28]. This effect was not observed with the
combination of lenalidomide and panitumumab, this finding being
justifiable by the fact that panitumumab is an IgG2 anti-EGFR
mAb without ADCC-inducing capacity.
Materials and Methods
Study design
This phase II, multicenter, open-label trial was conducted in
accordance with the ethical principles of the Declaration of
Helsinki and the Good Clinical Practice, according to the
International Conference on Harmonization of Technical Re-
quirements for Registration of Pharmaceuticals for Human Use.
The study protocol, the proposed informed consent form, and
other information to subjects, were approved by the Comitato
Etico-Scientifico, Ospedale Niguarda Ca’ Granda, Milan, Italy
and properly constituted Institutional Review Boards/Indepen-
dent Ethics Committees of all participating institutions. The
protocol for this trial and supporting CONSORT checklist are
available as supporting information; see Checklist S1 and Protocol
S1. The trial design consisted of a safety lead-in phase (phase IIa)
to determine the maximum tolerated dose (MTD) of lenalidomide
when combined with cetuximab, and a randomized phase IIb to
determine the response rate of the combination compared with
lenalidomide as a single agent (Figure 1). Phase IIb consisted of a
proof of concept (POC) part and an expansion part.
Patients
Patients were eligible to participate in this study if they were
diagnosed with metastatic colorectal adenocarcinoma with a
confirmed KRAS mutation status. Patients must have progressed
on oxaliplatin- and irinotecan-containing regimens, with at least
one of these regimens containing bevacizumab. Eastern Cooper-
ative Oncology Group performance status (ECOG PS) score of
patients was #1. Written informed consent was obtained from all
participants involved in the study.
Objectives
The primary objectives of this trial were to determine the MTD
and response rate of lenalidomide in combination with cetuximab.
Secondary objectives were to establish the safety, tolerability, and
clinical efficacy of the combination. Identifying biomarkers for
validation of clinical efficacy and toxicity was an exploratory
objective.
Adverse events (AEs) were graded using the National Cancer
Institute Common Terminology Criteria for Adverse Events (NCI
CTCAE) version 4.0 at each visit, with grade 5 representing deaths
related to AEs. An AE was considered to be treatment-emergent
(TEAE) if it occurred or worsened on or after the first treatment
with the study drug, and within 28 days after the last dose was
received. AEs were suspected to be related to the study drug if the
temporal relationship of the AE to the administration of
lenalidomide or cetuximab made a causal relationship possible,
and other medications, therapeutic interventions, or underlying
conditions did not provide a sufficient explanation for the observed
event. All patients who received at least 1 dose of study drug were
included in the safety analyses. Response rate and tumor
progression were to be determined per Response Evaluation
Criteria in Solid Tumors version 1.1.
Phase IIa
A total of 6–18 patients were planned to be enrolled into phase
IIa. Patients received oral lenalidomide at a starting dose of 25 mg
daily. Cetuximab was administered as a 400 mg/m2 initial
intravenous infusion, followed by 250 mg/m2 infusions on days
1, 8, 15, and 22 of each 28-day cycle. Dose escalation was not
allowed and treatment was to be continued until tumor
progression, unacceptable toxicity, death, or treatment discontin-
uation for any other reason.
The MTD of lenalidomide was defined as the highest dose level
at which no more than 1 out of 6 patients experienced a dose-
limiting toxicity (DLT). DLT was defined as missing at least 7 days
of lenalidomide and/or 1 dose of cetuximab during the first cycle
due to one or more of these drug-related AEs: any grade 3 or 4
non-hematological toxicity (excluding rash [treated and resolved
according to guidelines] and alopecia); or grade 4 neutropenia,
febrile neutropenia, or thrombocytopenia. If no more than 1 out of
6 subjects experienced a DLT in cycle 1, 25 mg lenalidomide
would be the MTD. If 2 subjects or more experienced a DLT,
then 6 additional subjects were to be enrolled at lower doses
(20 mg) of lenalidomide. If 2 subjects or more experienced a DLT
at this dose, the lenalidomide dose for the following 6 patients
would be 15 mg. If no more than 1 patient experienced a DLT,
that dose was determined to be the MTD. Patients experiencing a
DLT were allowed to continue treatment at a lower dose of
lenalidomide.
Phase IIb
In the POC part of phase IIb, 82 patients were planned to be
randomized at a 1:1 ratio to either continue the phase IIa
treatment schedule with lenalidomide at the MTD or to receive
oral lenalidomide monotherapy dosed at 25 mg/day. Proceeding
to the expansion part of phase IIb would be possible if the response
rate from either arm in the POC part was significantly more than
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10%. In the expansion part, patients were to be treated with the
phase IIa treatment schedule with lenalidomide at the MTD.
Follow-up
Patients were to be followed-up with one visit 28 days after the
last dose of study drug was administered and subsequent telephone
contacts for survival every 90 days until death or 5 years post-
discontinuation.
Biomarker analysis
A biomarker and pharmacodynamic marker analysis including
FccR genotyping, EGFR copy number, and immunomodulation
was performed in this study. FccR polymorphisms were
determined in paraffin tumor samples by Genoptix Medical
Laboratory (Carlsbad, CA) by DNA sequencing with allele-specific
polymerase chain reaction serving as a back-up assay when
required. EGFR gene copy number was analyzed in the Genoptix
Medical Laboratory on individual patients’ tumor specimens using
Figure 1. Study design and enrollment in patient groups. Study was terminated before the expansion part of phase IIb. *One patient was
randomized to the lenalidomide monotherapy group but discontinued before taking any study drug and was therefore excluded from the analyses.
AE, adverse event; ITT, intention to treat; PD, progressive disease.
doi:10.1371/journal.pone.0062264.g001
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a standard, validated fluorescent in situ hybridization (FISH)
protocol. It was scored by a pathologist as positive or negative for
EGFR amplification based on the following predetermined criteria:
positive if there were more than 4 EGFR copies in at least 40% of
cells or if the EGFR/chromosome 7 enumeration probe (CEP7)
ratio was .2 in over 10% of cells; negative if the ratio EGFR/
CEP7 was ,2 in over 90% of cells or there were less than 4 EGFR
copies in more than 60% of cells.
Sample size
During phase IIa, up to approximately 18 subjects were to be
enrolled. During the phase IIb POC part, up to approximately 82
subjects were to be randomized in a 1:1 ratio between the
lenalidomide plus cetuximab combination therapy arm and the
lenalidomide monotherapy arm. A Simon two stage minimax
design was used to monitor subject enrollment for each
randomization arm separately. In the first stage, 23 subjects were
to be enrolled. If 2 or less of the 23 subjects (,10%) had a response
in either arm, the enrollment for that arm was to be stopped. If
more than 2 of the 23 subjects had a response in either arm, the
enrollment in that arm was to be continued until 41 subjects were
enrolled. If one arm would be stopped, all new subjects were to be
enrolled in the remaining arm. At the final analysis, the regimen
would be concluded with a more than 10% true response rate if 9
or more of 41 subjects (.21%) have a response. This design had
90% power to conclude the true response rate higher than 10% at
one-sided 2.5% level when the true response rate is 30%.
When any arm from the phase IIb POC was considered
positive, the study would proceed with that regimen to the phase
IIb Expansion phase. In the Expansion phase, approximately 120
subjects were to be treated with the regimen. This sample size
would allow for a two sided 95% confidence interval of (22%,
39%) when 30% response rate is observed.
Results
Patient disposition
A total of 8 patients were enrolled into phase IIa of the study
(Figure 1). In the phase IIb POC, 43 patients were enrolled; 1
patient did not take any study drug and was therefore excluded
from the analyses.
Baseline characteristics
During the phase IIa, the median age was 60.5 years, all
patients were of Caucasian origin, there were equal numbers
males and females, and in 75% of patients the ECOG PS score
was 0 at baseline (Table 1).
The median age of the patients enrolled into phase IIb was 56
years, 97.6% were Caucasian and 57.1% were male. Baseline
ECOG PS score was 0 (57.1%) or 1 (40.5%), and 1 patient had a
score of 2. Types of KRAS mutations included 12ASP, 12VAL,
12CYS, 13ASP, 12ALA, 12ARG, and 12SER. The lenalidomide
plus cetuximab combination therapy arm and lenalidomide
monotherapy arm were well matched for demographics and
baseline characteristics.
Maximum tolerated dose
In phase IIa, 1 patient developed a DLT: a grade 3
hypersensitivity reaction to cetuximab which led to permanent
withdrawal of cetuximab therapy during Cycle 1. As this was the
only DLT in phase IIa, the MTD was determined at 25 mg
lenalidomide per day. This was used as the dose for phase IIb.
Safety
As exposure to cetuximab and lenalidomide was comparable
between the two phases of the study, safety results of both phases
are combined in this section.
Treatment-emergent adverse events. All 29 patients on
the combination regimen and 20 of the 21 patients on
lenalidomide monotherapy experienced at least one TEAE.
Overall, 54% and 93% of patients experienced at least 1 TEAE
that was suspected by the investigator to be related to lenalidomide
or cetuximab, respectively (Table 2). The most common AEs
related to lenalidomide were fatigue (26%), rash (26%), pruritus
(12%), and diarrhea and nausea (10% each). These AEs occurred
more frequently in patients treated with the lenalidomide plus
cetuximab combination regimen than with lenalidomide mono-
therapy. AEs most commonly attributed to cetuximab were rash
(59%), fatigue (31%), dry skin (28%), and erythema, skin fissures,
pruritus and stomatitis (14% each).
All TEAEs that were deemed related to one of the study drugs
were grade 3 or less. In 30% of patients AEs led to withdrawal of
lenalidomide and in 34% led to dose reductions or interruptions of
lenalidomide; withdrawal of cetuximab occurred in 31% of
patients and dose reductions or interruptions of cetuximab were
recorded in 28% of patients.
Fifteen patients had abnormal laboratory values that were
reported as AEs, with an equal frequency in the lenalidomide
monotherapy and lenalidomide plus cetuximab combination
treatment groups. These AEs were mostly related to liver function
and included increases in bilirubin, alanine aminotransferase,
aspartate aminotransferase, alkaline phosphatase (ALP), and
lactate dehydrogenase.
Severity of events. Overall, the majority of the TEAEs were
NCI CTCAE grades 1 and 2. In the lenalidomide plus cetuximab
combination therapy groups, 55% of patients experienced an AE
of grade 3 or more, and in the lenalidomide monotherapy group
this was 62%. Three grade 4 AEs occurred in the lenalidomide
monotherapy arm (constipation, hyperbilirubinemia, and in-
creased blood ALP); none occurred in the lenalidomide plus
cetuximab combination therapy arms.
A total of 46% of patients experienced a serious AE (SAE); 43%
of the lenalidomide monotherapy group and 48% of the
lenalidomide plus cetuximab combination treatment groups. SAEs
reported in more than 1 patient were general physical health
deterioration (5 patients; 3 patients in the lenalidomide plus
cetuximab combination treatment arms and 2 patients in the
lenalidomide monotherapy arm), diarrhea, hyperbilirubinemia,
and dyspnea (2 patients; both in the lenalidomide plus cetuximab
combination treatment arms), abdominal pain (2 patients; both in
the lenalidomide monotherapy arm), asthenia, infection, and
pyrexia (1 patient in the lenalidomide monotherapy treatment arm
and 1 patient in the lenalidomide plus cetuximab combination
treatment arm).
Mortality. Thirty-nine patients (78%) died during the study.
Three patients had causes of death listed other than disease
progression (pulmonary embolism, respiratory failure, and septic
shock), though the pulmonary embolism and respiratory failure
were later found to be associated with disease progression.
Nine deaths were reported as grade 5 AEs. Five grade 5 AEs
occurred in the lenalidomide monotherapy arm (metastasis to
liver, metastasis to lung, large intestine perforation, and 2 events of
general physical health deterioration) and 4 in the combination
therapy arms (pulmonary embolism, general physical health
deterioration, septic shock, and respiratory failure).
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Treatment duration and exposure
In phase IIa, the median duration of lenalidomide treatment
was 8.1 weeks with a median dose intensity of 25 mg/day and a
median relative dose intensity of 100% (Table 3). The median
duration of cetuximab treatment was 7.1 weeks, with a median
dose intensity of 287.9 mg/m2/week and a median relative dose
intensity of 115.1%.
In phase IIb, the median duration of lenalidomide treatment
was 8 weeks with a median dose intensity of 25 mg/day for both
treatment arms. The median relative dose intensity was 100% in
both arms. The median duration of cetuximab treatment was 7.1
weeks, with a median dose intensity of 301 mg/m2/week and a
median relative dose intensity of 120.4%.
Efficacy
Based on Biomedical System Corporation imaging data, the
best response was stable disease in 9 patients, 1 patient from phase
IIa and 8 patients from phase IIb, 5 of whom were treated with
lenalidomide plus cetuximab combination treatment and 3 of
whom were treated with lenalidomide monotherapy. Enrollment
for the trial was, therefore, stopped, and the study was terminated
prior to the expansion part of phase IIb due to lack of efficacy in
any of the treatment arms and failure to achieve the planned
response objective. Therefore, further efficacy and survival
information were not collected and the secondary efficacy
endpoints (PFS, response duration, disease control rate, and OS)
were not analyzed.
All patients discontinued the study (Figure 2). In phase IIa, the
reasons for discontinuation were disease progression in 6 patients,
AEs in 1 patient, and death in 1 patient. In phase IIb,
discontinuation was related to disease progression (76.2%;
66.7% in the lenalidomide monotherapy arm and 85.7% in the
lenalidomide plus cetuximab combination therapy arm), AEs
(14.3%), death (7.1%), and other reasons (2.4%).
Biomarker analysis
A total of 27 subjects treated with lenalidomide plus cetuximab
(from both phases IIa and IIb) have been analyzed for the
correlative analysis of FccR genotyping and OS–defined as the
time from the date of randomization to the date of death (any
cause). Patients that did not die were censored at the last known
time the patient was alive. Kaplan-Meier curves were plotted and
a log-rank p value was used to test the difference in OS between
genotype groups (Figure S1 and Figure S2). No significant
difference in OS was observed between the different genotype
groups defined by either FccRIIA or IIIA among these 27 subjects
(log-rank p value .0.05). In contrast, the correlative analysis of
EGFR gene copy number status (FISH-positive or FISH-negative)
and OS in the 23 subjects who received lenalidomide plus
cetuximab combination therapy showed that OS was significantly
longer in EGFR FISH-positive than in EGFR FISH-negative
subjects (log-rank p value = 0.0294) (Figure S3). Similar results
were observed in the 20 subjects who received lenalidomide
monotherapy (log-rank p value = 0.0582) (Figure S4). Significant
immunomodulating effects were observed and a separate report on
the immunomodulatory effects is forthcoming.
Table 1. Baseline characteristics phase IIa and IIb.
Characteristic Phase IIa Phase IIb
Lenalidomide+
cetuximab (n=8)
Lenalidomide
(n =21)
Lenalidomide+
cetuximab (n=21) Overall (N=42)
Age, years Median (range) 60.5 (45.0–70.0) 54.0 (38.0–75.0) 57.0 (31.0–70.0) 56.0 (31.0–75.0)
#65 years 7 (87.5%) 16 (76.2%) 18 (85.7%) 34 (81.0%)
.65 years 1 (12.5%) 5 (23.8%) 3 (14.3%) 8 (19.0%)
Sex Male 4 (50.0%) 12 (57.1%) 12 (57.1%) 24 (57.1%)
Female 4 (50.0%) 9 (42.9%) 9 (42.9%) 18 (42.9%)
Race Caucasian 8 (100%) 21 (100%) 20 (95.2%) 41 (97.6%)
Non-caucasian 0 0 1 (4.8%) 1 (2.4%)
ECOG PS score 0 6 (75.0%) 10 (47.6%) 14 (66.7%) 24 (57.1%)
1 2 (25.0%) 10 (47.6%) 7 (33.3%) 17 (40.5%)
2 0 1 (4.8%) 0 1 (2.4%)
KRAS mutationsa 12ASP 3 (37.5%) 5 (23.8%) 8 (38.1%) 13 (31.0%)
12VAL 2 (25.0%) 5 (23.8%) 3 (14.3%) 8 (19.0%)
12CYS 1 (12.5%) 2 (9.5%) 4 (19.0%) 6 (14.3%)
13ASP 0 2 (9.5%) 1 (4.8%) 3 (7.1%)
12ALA 0 2 (9.5%) 0 2 (4.8%)
12ARG 0 0 2 (9.5%) 2 (4.8%)
12SER 0 1 (4.8%) 0 1 (2.4%)
N.a.b 2 (25.0%) 2 (9.5%) 2 (9.5%) 4 (9.5%)
Negativeb 0 2 (9.5%) 1 (4.8%) 3 (7.1%)
aKRAS mutations as determined by Genoptix Medical Laboratory.
bKRAS mutation found in local laboratory.
Abbreviations: ECOG PS: Eastern Cooperative Oncology Group performance status; n.a.: not applicable.
doi:10.1371/journal.pone.0062264.t001
Lenalidomide+Cetuximab in KRAS-Mutant mCRC
PLOS ONE | www.plosone.org 5 November 2013 | Volume 8 | Issue 11 | e62264
Discussion
Currently, the National Comprehensive Cancer Network
clinical practice guidelines [9] recommend KRAS-mutant CRC
patients with metastatic or advanced disease to be treated with
chemotherapy regimens including oxaliplatin, leucovorin, 5-
fluorouracil, bevacizumab, capecitabine, and irinotecan. These
compounds are used in both first- and second-line treatment
regimens [9]. However, if patients are unsuitable for intensive
therapy, treatment options are either 5-fluorouracil combined with
leucovorin, or capecitabine with or without bevacizumab. If
patients relapse or their functional status does not improve with
treatment, the remaining treatment option is best supportive care
[9]. This is the first study to assess the safety and efficacy of a
combination regimen with cetuximab and lenalidomide in
previously treated KRAS-mutant mCRC patients.
Lenalidomide has shown to significantly reduce tumor growth
and cause necrosis in tumors in a CRC mouse model [27].
Additionally, when lenalidomide was combined with cetuximab in
a CRC cell line, it enhanced NK cell-mediated lysis of CRC cells
by ADCC, independent of KRAS mutational status [28]. Following
these preclinical results, we hypothesized that the combination of
Table 2. TEAEs suspected by the investigator to be related to study drug, occurring in $2 patients, sorted by overall incidence.
Phase IIa Phase IIb
Lenalidomide+cetuximab (n =8)
Lenalidomide
(n =21) Lenalidomide+cetuximab (n=21)
Related to
lenalidomide
Related to
cetuximab
Related to
lenalidomide
Related to
lenalidomide
Related to
cetuximab
Patients with $1 TEAE related to study drug 5 (62.5%) 8 (100%) 9 (42.9%) 13 (61.9%) 19 (90.5%)
TEAEs grade $3a 4 (50.0%) 6 (75.0%) 6 (28.6%) 5 (23.8%) 12 (57.1%)
Rash 2 (25.0%) 5 (62.5%) 4 (19.0%) 7 (33.3%) 12 (57.1%)
Fatigue 3 (37.5%) 3 (37.5%) 3 (14.3%) 7 (33.3%) 6 (28.6%)
Dry skin 1 (12.5%) 3 (37.5%) 0 2 (9.5%) 5 (23.8%)
Pruritus 2 (25.0%) 2 (25.0%) 2 (9.5%) 2 (9.5%) 2 (9.5%)
Diarrhea 2 (25.0%) 1 (12.5%) 0 3 (14.3%) 2 (9.5%)
Stomatitis 1 (12.5%) 2 (25.0%) 0 1 (4.8%) 2 (9.5%)
Erythema 1 (12.5%) 2 (25.0%) 0 0 2 (9.5%)
Nausea 1 (12.5%) 0 1 (4.8%) 3 (14.3%) 0
Skin fissures 0 1 (12.5%) 0 1 (4.8%) 3 (14.3%)
Dyspnea 1 (12.5%) 1 (12.5%) 0 2 (9.5%) 0
Pyrexia 0 1 (12.5%) 1 (4.8%) 1 (4.8%) 1 (4.8%)
Anorexia 2 (25.0%) 1 (12.5%) 0 0 0
Hypokalemia 1 (12.5%) 1 (12.5%) 0 1 (4.8%) 0
Paronychia 0 3 (37.5%) 0 0 0
Hypomagnesemia 0 1 (12.5%) 0 1 (4.8%) 1 (4.8%)
Dysgeusia 0 0 1 (4.8%) 1 (4.8%) 1 (4.8%)
Mucosal inflammation 0 0 0 2 (9.5%) 1 (4.8%)
Vomiting 1 (12.5%) 0 0 1 (4.8%) 1 (4.8%)
Neutropenia 0 0 1 (4.8%) 1 (4.8%) 0
General physical health deterioration 1 (12.5%) 1 (12.5%) 0 0 0
Arthralgia 1 (12.5%) 1 (12.5%) 0 0 0
Photosensitivity reaction 1 (12.5%) 1 (12.5%) 0 0 0
Hypersensitivity 0 1 (12.5%) 0 0 1 (4.8%)
Skin hyperpigmentation 0 1 (12.5%) 0 0 1 (4.8%)
Hypertrichosis 0 1 (12.5%) 0 0 1 (4.8%)
Tachycardia 0 1 (12.5%) 0 1 (4.8%) 0
Vulvovaginal mycotic infection 0 0 0 1 (4.8%) 1 (4.8%)
Enteritis 0 0 0 1 (4.8%) 1 (4.8%)
Muscle spasms 0 0 0 1 (4.8%) 1 (4.8%)
Headache 0 0 0 2 (9.5%) 0
aAll grade $3 TEAEs related to study drug were grade 3. Grade 3 events related to lenalidomide: fatigue (7; 2 events in 2 patients each), neutropenia (2), anorexia,
hypokalemia, general physical health deterioration, diarrhea, increased gamma-glutamyltransferase, and decreased blood potassium. Grade 3 events related to
cetuximab: rash (4; 3 events in 1 patient), fatigue (4; 2 events in 1 patient), hypersensitivity (3; 2 events in 1 patient), diarrhea (2), urticaria, general physical health
deterioration, tachycardia, dyspnea, and hypertension.
doi:10.1371/journal.pone.0062264.t002
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lenalidomide and cetuximab could be active in patients with
KRAS-mutated mCRC.
In the phase IIa part of this study, the median relative dose
intensity was 100% for lenalidomide and 115.1% for cetuximab,
even though no dose escalation was allowed in this phase of the
trial. This is likely due to the relatively short treatment duration
after the initial cetuximab dose of 400 mg/m2 and the fact that the
relative dose intensity is defined as the dose intensity divided by the
planned dose intensity, where the dose intensity is cumulative dose
divided by treatment duration, and the planned dose intensity was
250 mg/m2/week.
With this dose intensity, only 1 DLT was reported during the
dose finding phase and lenalidomide 25 mg/day was determined
to be the MTD. The safety profile for lenalidomide and cetuximab
in this study is consistent with that observed for lenalidomide in
other non-hematological malignancies [29–31] and with that
reported for cetuximab in this patient population [13]. In phase
IIb of this study, stable disease was the best response seen in both
the lenalidomide monotherapy and the lenalidomide plus cetux-
imab combination therapy arms. Therefore, enrollment was
stopped prematurely. Safety and tolerability were evaluated
throughout the study, but additional efficacy information for
enrolled patients was not collected.
There are three distinct classes of FccR that bind the Fc portion
of IgG: FccRI (CD64), FccRII (CDw32), and FccRIII (CD16).
The FccRII receptor is an immunoglobulin expressed on the
Table 3. Median treatment duration, cumulative dose, dose intensity, and relative dose intensity.
Phase IIa Phase IIb
Lenalidomide+cetuximab (n =8) Lenalidomide (n =21) Lenalidomide+cetuximab (n =21)
Median (range) Lenalidomide exposure Cetuximab exposure Lenalidomide exposure Lenalidomide exposure Cetuximab exposure
Treatment duration
(weeks)a
8.1 (4–16.4) 7.1 (2.1–16) 8 (0.7–33) 8 (2.3–24.1) 7.1 (1.3–23.1)
Cumulative dose (mg or
mg/m2)b
1,412.5 (675–2,875) 1,897.8 (900–4,400) 1,375 (125–4,875) 1,400 (400–3,875) 2,148.4 (650–5,400)
Dose intensity (mg/week
or mg/m2/week)c
175 (169–175) 288 (268–420) 175 (108–175) 175 (131–175) 301 (203–506)
Relative dose intensity
(%)d
100 (96–100) 115.1 (107–168) 100 (61–100) 100 (75–100) 120.4 (81–202)
aTreatment duration= [(the study treatment end date)2(the first study drug start date)+1]/7.
bCumulative dose = total doses taken during treatment phase.
cDose intensity = cumulative dose/treatment duration.
dRelative dose intensity = dose intensity/planned dose intensity6100.
doi:10.1371/journal.pone.0062264.t003
Figure 2. Reasons for discontinuation. One patient in the lenalidomide monotherapy group of phase IIb discontinued on investigator’s decision
due to lack of efficacy, mentioned as ‘‘other’’ in the figure.
doi:10.1371/journal.pone.0062264.g002
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surface of macrophages and neutrophils. A single nucleotide
polymorphism (SNP) found in FccRIIA results in two allotypes
with either arginine (R) or histidine (H) at codon 131 [17]. The
FccRIIA 131 H/H has been found to bind IgG1 with a higher
affinity than R/R homozygotes and H/R or R/H heterozygotes.
The FccRIIIA receptor is an immunoglobulin expressed on the
surface of NK cells, monocytes, some T cells, and macrophages. A
SNP found in FccRIIIA results in two allotypes with either valine
(V) or phenylalanine (F) at codon 158. IgG binds in the region
proximal to amino acid 158, and the FccRIIIA 158 V/V has been
found to bind IgG1 with a higher affinity than F/F homozygotes
and V/F or F/V heterozygotes. These polymorphisms at FccRIIA
codon 131 and FccRIIIA codon 158 may play a role in immune
activation and explain the variability of cetuximab-mediated
clinical responses [32,33]. In this study, the correlative analysis of
OS and FccRIIA or IIIA genotype showed that OS did not
correlate with any particular genotype. This lack of correlation
may support the finding that any prolongation of OS observed in
the study population was not associated with lenalidomide
enhancing ADCC because the binding affinity of cetuximab
played no role in predicting OS.
The biomarker analysis showed that in patients with EGFR
FISH-positive tumors, i.e., CRC with increased EGFR gene copy
number, OS was significantly longer than in EGFR FISH-negative
subjects. Therefore, EGFR copy number might be of value as a
prognostic marker. For subjects treated with lenalidomide plus
cetuximab combination therapy, this finding is consistent with
published reports of improved survival in patients with mCRC and
high EGFR copy numbers who receive treatment with cetuximab
[34–36]. However, the observation of an association between high
EGFR copy number and OS in the lenalidomide monotherapy
arm is inconclusive because of the small sample size. It should also
be considered that assessment of EGFR gene copy number by
FISH may be hampered by difficulties in clinical inter-laboratory
reproducibility [37].
In conclusion, the combination regimen appeared to be well-
tolerated and the toxicity profile of lenalidomide plus cetuximab
combination therapy was similar to that of lenalidomide mono-
therapy. However, the short duration of exposure and small
patient numbers limit drawing a definitive conclusion regarding
safety. Despite preclinical evidence, present clinical data suggest
the modulating effect of lenalidomide is unable to overcome
primary resistance of KRAS-mutant mCRC to EGFR targeted
inhibition by cetuximab. The combination of lenalidomide and
cetuximab does not appear to demonstrate clinically meaningful
activity in the treatment of KRAS-mutant mCRC patients.
Supporting Information
Figure S1 FccRIIA genotype and overall survival (OS) in the
lenalidomide plus cetuximab combination therapy arm. There are
no significant differences in OS among the three genotype groups
for FccRIIA. The median OS is 194, 129, and 152 days for the
‘‘H/H’’, ‘‘H/R’’, and ‘‘R/R’’ groups, respectively.
(TIF)
Figure S2 FccRIIIA genotype and overall survival (OS) in the
lenalidomide plus cetuximab combination therapy arm. There are
no significant differences in OS among the three genotype groups
for FccRIIIA. The median OS is 176, 152, and 111 days for the
‘‘F/F’’, ‘‘F/V’’, and ‘‘V/V’’ groups, respectively.
(TIF)
Figure S3 Epidermal growth factor receptor (EGFR) copy
number and overall survival (OS) in the lenalidomide plus
cetuximab combination therapy arm. In the lenalidomide plus
cetuximab combination therapy arm, OS was significantly shorter
for EGFR FISH-negative than for EGFR FISH-positive subjects
(median OS: 150 and.336 days, respectively). One subject whose
EGFR status was tested twice by Genoptix had a negative and a
positive result, and was considered EGFR FISH-positive for this
analysis.
(TIF)
Figure S4 Epidermal growth factor receptor (EGFR) copy
number and overall survival (OS) in the lenalidomide monother-
apy arm. In the lenalidomide monotherapy arm, OS was shorter
for EGFR FISH-negative than for EGFR FISH-positive subjects
(median OS: 86 and .277 days, respectively).
(TIF)
Checklist S1 CONSORT Checklist.
(DOC)
Protocol S1 Trial Protocol.
(PDF)
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